Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Claire on +44 1494 818 025 or claire@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Claire Roberts
Director
claire@zenopa.com
+44 1494 818 025

Testimonials
I have had a different experience dealing with Zenopa, and feel without the support I may not have had the critical edge in the assessment centre.
Showab, 2012

Novo Nordisk launches FlexTouch insulin pen

11 October 2011 00:00 in Pharmaceutical Company Product News


Novo Nordisk has introduced its new disposable prefilled insulin pen device FlexTouch in the UK.

The new product is designed for use with the company's rapid-acting modern insulin analogue NovoRapid and allows insulin to be administered at any dose, from 1 to 80 units, via a single button press.

A spring incorporated into its unique design means the device itself is able to absorb the force of the injection, making it extremely easy to use, while also setting apart from other products of the same type.

Novo Nordisk is making the FlexTouch pen available in order to provide a new therapy option that will help diabetes patients to manage their condition with as little disruption to their lives as possible.

Viggo Birch, managing director for Novo Nordisk, said: "Novo Nordisk is committed to continually improving our diabetes medicines and devices that can help solve some of the major challenges people with diabetes face every day."

Last month, the company published new clinical trial data for its new diabetes therapy insulin degludec, showing the glycaemic control benefits the treatment can offer.ADNFCR-8000103-ID-800754520-ADNFCR

Other news stories from 11/10/2011

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd